Replies to post #189627 on Biotech Values

[DewDiligence]

I wonder if EGRX’s low-sodium Bendamustine patent will stand up to scrutiny; the invention seems rather obvious:

http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=9,000,021.PN.&OS=PN/9,000,021&RS=PN/9,000,021

Note: This patent isn’t necessary to defend the rapid-infusion formulation of Treanda that Teva recently licensed.